BioCopy AG Raises $8M to Transform Next-Generation Cancer Drug Development with AI-Driven Biotherapeutics

BioCopy AG is excited to announce a successful funding round in which the company raised 8,000,000, marking a significant milestone in its mission to revolutionize cancer therapeutics. With headquarters in Basel, Switzerland, and a state-of-the-art R&D facility in Emmendingen, Germany, BioCopy is strategically positioned at the interface of cutting-edge biotechnology and artificial intelligence. This new infusion of capital will accelerate the on-going development and deployment of next-generation cancer drugs, designed to drastically improve the chance for a cure. By integrating AI with its automated end-to-end engineering platform, BioCopy is reshaping the pharmaceutical industry by transforming the traditional research and development timeline—from an estimated three years down to just twelve months—thereby saving valuable time and reducing costs in the fight against cancer. This funding not only fuels the rapid development of highly effective and safe biotherapeutics but also enhances the quality and quantity of data generation. The comprehensive datasets produced are central to leveraging AI’s full potential and are unparalleled within the industry. In addition to advancing cancer treatments, BioCopy’s long-term vision includes expanding its research efforts into the realms of immunological and neurological diseases, aiming to offer innovative solutions for several critical health challenges. Under the expert leadership of Dr. Matthias Wiedenfels, a proven industry insider with an impressive track record from his tenure as CEO of STADA Arzneimittel AG, BioCopy is energized to push the boundaries of biotech innovation. This achievement reinforces the company’s commitment to delivering breakthrough solutions and underscores its role as a transformative force in modern therapeutics.